Unityca Tablets 90 mg (Ticagrelor)

Adult dose

Do not use this medicine concomitantly with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg per dose twice daily. Treatment for 12 months is recommended unless discontinuation of this medicine is clinically necessary. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg per dose twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients who were taking 90mg of this medicine or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with 60mg of this medicine. Treatment with this medicine may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). The safety and efficacy of this medicine were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg per dose twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. For patients with acute coronary syndrome, refer to the corresponding dosage and administration instructions. Data on the safety and efficacy of this medicine for treatment longer than 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg, followed by 90mg per dose twice daily for 30 days. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended in patients with acute ischemic stroke or high-risk transient ischemic attack. This medicine is administered orally and may be taken with or without food. For patients who have difficulty swallowing tablets, crush this medicine into a fine powder, disperse it in half a glass of water, and drink the mixture. Rinse the glass used for administration with half a glass of water and drink again. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the nasogastric tube with water after administration. When switching from another antiplatelet agent to this medicine, start this medicine 24 hours after the last dose of the previous medicine. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is necessary in patients with renal impairment. No dose adjustment is necessary in patients with mild hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment, and experience with its use in patients with moderate hepatic impairment is limited.

Child dose

The safety and efficacy in pediatric patients younger than 18 years have not been established (see the 'Other' section).

This medication prevents the formation of blood clots by inhibiting blood coagulation. However, it may increase the risk of bleeding, so it should not be used in patients with active pathological bleeding or a history of brain hemorrhage. If surgery is planned, this medication should be discontinued at least 5 days prior to the procedure, and if any bleeding symptoms occur, consult a doctor immediately. This medication can interact with certain drugs, so inform your healthcare provider if you are taking any other medications. Caution is advised in patients at high risk of bleeding or those with severe liver dysfunction, as well as in patients taking specific medications. Symptoms such as dyspnea or bradycardia (slower heart rate) may occur, requiring careful monitoring. Women who are pregnant or breastfeeding should consult a doctor before taking this medication, and it is not recommended for children under 18 years old. In cases of overdose, the risk of bleeding may increase, and emergency treatment should be sought immediately; this medication is not removed through dialysis. Patients may experience dizziness or confusion while taking this medication, so care is needed when driving or operating machinery. This medication should be taken strictly according to a doctor's prescription and instructions, and should not be arbitrarily discontinued or dosage changed.

• Hemorrhage
• hypotension
• confusion
• dizziness
• syncope
• headache
• vertigo
• dyspnea
• diarrhea
• nausea

This medication is sensitive to air and moisture, so it should be stored in a tightly closed container. The appropriate storage temperature is between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness.

Appearance

Yellow, round, double convex film-coated tablet

Package unit

56 tablets/box [(14 tablets PTP x 4)]